Marker Therapeutics, Inc. (NASDAQ: MRKR) had its "strong-buy" rating re-affirmed by analysts at WBB Securities. They now have a $12.50 price target on the stock.
Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Marker Therapeutics, Inc. (NASDAQ: MRKR) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference [Yahoo! Finance]